

List of publications (peer reviewed research articles)

1. König D, Neubauer O, **Nics L**, Kern N, Berg A, Bisse E, Wagner KH. Biomarkers of exercise-induced myocardial stress in relation to inflammatory and oxidative stress. *Exerc Immunol Rev.* 2007;13:15-36.
2. Neubauer O, König D, Kern N, **Nics L**, Wagner KH. No indications of persistent oxidative stress in response to an ironman triathlon. *Med Sci Sports Exerc.* 2008;40(12):2119-28.
3. Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, **Nics L**, Lanzenberger R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Spreitzer H, Wadsak W. Automatisation and first evaluation of [¹⁸F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [¹⁸F]FE@SUPPY. *The Open Nuclear Medicine Journal.* 2009;1:15-23.
4. Haeusler D, Mien LK, **Nics L**, Ungersboeck J, Phillippe C, Lanzenberger R, Kletter K, Dudczak R, Mitterhauser M, Wadsak W. Simple and rapid preparation of [¹¹C]DASB with high quality and reliability for routine applications. *Appl Radiat Isot.* 2009;67(9):1654-60.
5. Haeusler D, Mitterhauser M, Mien L.K, Shanab K, Lanzenberger R, Schirmer E, Ungersboeck J, **Nics L**, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W. Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[¹⁸F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY:2). *Radiochim Acta.* 2009;97:753-58.
6. Wagner KH, Reichhold S, Holzl C, Knasmuller S, **Nics L**, Meisel M, Neubauer O. Well-trained, healthy triathletes experience no adverse health risks regarding oxidative stress and DNA damage by participating in an ultra-endurance event. *Toxicology.* 2010;278(2):211-6.
7. Haeusler D, **Nics L**, Ungersboeck J, Mien LK, Lanzenberger R, Shanab K, Sindelar KM, Viernstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M. [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 -metabolic considerations. *Nucl Med Biol.* 2010;37(4):421-6. (the authors Haeusler and Nics contributed equally).
8. **Nics L**, Haeusler D, Wadsak W, Wagner KH, Dudczak R, Kletter K, Mitterhauser M. The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: there is no difference. *Nucl Med Biol.* 2010;38(1):13-7.
9. Neubauer O, Reichhold S, **Nics L**, Hoelzl C, Valentini J, Stadlmayr B, Knasmüller S, Wagner KH. Antioxidant responses to an acute ultra-endurance exercise: impact on DNA stability and indications for an increased need for nutritive antioxidants in the early recovery phase. *Br J Nutr.* 2010;104(8):1129-38.
10. Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, **Nics L**, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network viaserotonin-1A receptors. *Proc Natl Acad Sci.* 2012;109(7):2619-24.
11. Hahn A, **Nics L**, Baldinger P, Ungersboeck J, Dolliner P, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input

functions enables quantification of serotonin-1A receptors with [carbonyl-¹¹C]WAY-100635 independent of arterial sampling. *Neuroimage*. 2012;62(1):199-206 (the authors Hahn and Nics contributed equally).

12. Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, **Nics L**, Zeilinger M, Shanab K, Lanzenberger R., Karanikas G, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. [¹⁸F]FE@SNAP -a new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): microfluidic and vessel-based approaches. *Bioorg Med Chem*. 2012;20(19):5936-40.
13. **Nics L**, Hahn A, Zeilinger M, Vranka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner KH, Dudczak R, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-¹¹C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel. *Appl Radiat Isot*. 2012;70(12):2730-6.
14. Mark C, Bornatowicz B, Mitterhauser M, Hendl M, **Nics L**, Haeusler D, Lanzenberger R, Berger ML, Spreitzer H, Wadsak W. Development and automation of a novel NET-PET tracer: [¹¹C]Me@APPI. *Nucl Med Biol*. 2013;40(2):295-303.
15. Hahn A, **Nics L**, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W, Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous input functions in major depression using [carbonyl-(¹¹C)]WAY-100635. *Nucl Med Biol*. 2013;40(3):371-7.
16. Rami-Mark C, Ungersboeck J, Haeusler D, **Nics L**, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G, Wadsak W. Reliable set-up for in-loop ¹¹C-carboxylations using Grignard reactions for the preparation of [carbonyl-¹¹C]WAY-100635 and [¹¹C]-(+)-PHNO. *Appl Radiat Isot*. 2013;82:75-80.
17. Philippe C, **Nics L**, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [¹⁸F]FE@SNAP: a new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1). *Sci Pharm*. 2013;81(3):625-39
18. Philippe C, **Nics L**, Zeilinger M, Kuntner C, Wanek T, Mairinger S, Shanab K, Spreitzer H, Viernstein H, Wadsak W, Mitterhauser M. Preclinical in vitro & in vivo evaluation of [(¹¹C)]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1. *Nucl Med Biol*. 2013;40(7):919-25
19. Rami-Mark C, Bornatowicz B, Fink C, Otter P, Ungersboeck J, Vranka C, Haeusler D, **Nics L**, Spreitzer H, Hacker M, Mitterhauser M, Wadsak W. Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(¹¹C)]IPCIT and [(¹⁸F)]FE@IPCIT. *Bioorg Med Chem*. 2013;21(24):7562-9
20. Haeusler D, Kuntner C, **Nics L**, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Wadsak W, Hacker M, Mitterhauser M. [¹⁸F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. *Eur J Nucl Med Mol Imaging*. 2015;42(5):741-9

21. Rami-Mark C, Eberherr N, Berroterán-Infante N, Vanicek T, **Nics L**, Lanzenberger R, Hacker M, Wadsak W, Mitterhauser M. [(18)F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism. *Nucl Med Biol.* 2016;43(8):490-5.
22. Hahn A, Gryglewski G, **Nics L**, Hienert M, Rischka L, Vranka C, Sigurdardottir H, Vanicek T, James GM, Seiger R, Kautzky A, Silberbauer L, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸F-FDG. *J Nucl Med.* 2016;57(12):1933-1940.
23. Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroterán-Infante N, **Nics L**, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. *Neuroimage.* 2017;149:23-32.
24. Zeilinger M, Pichler F, **Nics L**, Wadsak W, Spreitzer H, Hacker M, Mitterhauser M. New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. *EJNMMI Res.* 2017;7(1):22.
25. Vranka C, **Nics L**, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. LogP, a yesterday's value? *Nucl Med Biol.* 2017;50:1-10.
26. Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, **Nics L**, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos É, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. *Clin Pharmacol Ther.* 2018;104(1):139-147.
27. Hahn A, Gryglewski G, **Nics L**, Rischka L, Ganger S, Sigurdardottir H, Vranka C, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. *Brain Struct Funct.* 2018;223(3):1369-1378.
28. **Nics L**, Steiner B, Klebermass EM, Philippe C, Mitterhauser M, Hacker M, Wadsak W. Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. *Nucl Med Biol.* 2018;57:28-33.
29. Balber T, Singer J, Berroterán-Infante N, Dumanic M, Fetty L, Fazekas-Singer J, Vranka C, **Nics L**, Bergmann M, Pallitsch K, Spreitzer H, Wadsak W, Hacker M, Jensen-Jarolim E, Viernstein H, Mitterhauser M. Preclinical In Vitro and In Vivo Evaluation of [¹⁸F]FE@SUPPLY for Cancer PET Imaging: Limitations of a Xenograft Model for Colorectal Cancer. *Contrast Media Mol Imaging.* 2018;2018:1269830.
30. Philippe C, Mairinger S, Pichler V, Stanek J, **Nics L**, Mitterhauser M, Hacker M, Wanek T, Langer O, Wadsak W. Comparison of fully-automated radiosyntheses of [¹¹C]erlotinib for preclinical and clinical use starting from in target produced [¹¹C]CO₂ or [¹¹C]CH₄. *EJNMMI Radiopharm Chem.* 2018;3(1):8.

31. Pichler V, Berroterán-Infante N, Philippe C, Vranka C, Klebermass EM, Balber T, Pfaff S, **Nics L**, Mitterhauser M, Wadsak W. An Overview of PET Radiochemistry, Part 1: The Covalent Labels ¹⁸F, ¹¹C, and ¹³N. *J Nucl Med*. 2018;59(9):1350-1354.
32. Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, **Nics L**, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. Effect of Rifampicin on the Distribution of [¹¹C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. *Mol Pharm*. 2018;15(10):4589-4598.
33. Bauer M, Karch R, Wulkersdorfer B, Philippe C, **Nics L**, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. *J Nucl Med*. 2018 Sep 20. pii: jnumed.118.216432. doi: 10.2967/jnumed.118.216432.
34. Spies M, James GM, Vranka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, **Nics L**, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. *Transl Psychiatry*. 2018;8(1):198.
35. James GM, Gryglewski G, Vanicek T, Berroterán-Infante N, Philippe C, Kautzky A, **Nics L**, Vranka C, Godbersen GM, Unterholzner J, Sigurdardottir HL, Spies M, Seiger R, Kranz GS, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R. Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. *Cereb Cortex*. 2019;29(1):372-382.
36. Pichler V, Zenz T, Philippe C, Vranka C, Berroterán-Infante N, Pfaff S, **Nics L**, Ozenil M, Langer O, Willeit M, Traub-Weidinger T, Lanzenberger R, Mitterhauser M, Hacker M, Wadsak W. Molar activity - The keystone in ¹¹C-radiochemistry: An explorative study using the gas phase method. *Nucl Med Biol*. 2018;67:21-26.
37. Tournier N, Bauer M, Pichler V, **Nics L**, Klebermass EM, Bammingner K, Matzneller P, Weber M, Karch R, Caille F, Auvity S, Marie S, Jaeger W, Wadsak W, Hacker M, Zeitlinger M, Langer O. Impact of P-glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹C-Metoclopramide Assessed with PET Imaging in Humans. *J Nucl Med*. 2019 Jan 10. pii: jnumed.118.219972. doi: 10.2967/jnumed.118.219972.
38. Pfaff S, Philippe C, **Nics L**, Berroterán-Infante N, Pallitsch K, Rami-Mark C, Weidenauer A, Sauerzopf U, Willeit M, Mitterhauser M, Hacker M, Wadsak W, Pichler V. Toward the optimization of (+)-[¹¹C]PHNO synthesis: time reduction and process validation. *Contrast Media Mol Imaging*. 2019; (under review)